Other Health

Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15

Retrieved on: 
Wednesday, April 3, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Conference, Medication, DSM-IV codes

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Dr. Randall Kaye, Longboard’s Chief Medical Officer, will present late-breaking data from the PACIFIC Study evaluating bexicaserin, an oral, centrally acting 5-HT2C receptor superagonist, in participants with Developmental and Epileptic Encephalopathies (DEEs) at the AAN Annual Meeting taking place April 13-18, 2024, virtually and in Denver, Colorado.

Key Points: 
  • Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Dr. Randall Kaye, Longboard’s Chief Medical Officer, will present late-breaking data from the PACIFIC Study evaluating bexicaserin, an oral, centrally acting 5-HT2C receptor superagonist, in participants with Developmental and Epileptic Encephalopathies (DEEs) at the AAN Annual Meeting taking place April 13-18, 2024, virtually and in Denver, Colorado.
  • These data will also be presented at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII), which will take place in Madrid, Spain, May 5-8, 2024.

Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Thursday, April 4, 2024
Infectious Diseases, Clinical Trials, Stem Cells, Biotechnology, Other Health, Health, Other Science, Science, Oncology, Webcast, Patient, Conference, Cancer

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, at 12:45 p.m.

Key Points: 
  • Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, at 12:45 p.m.
  • ET.
  • A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in the Investors section.
  • A replay of the webcast will be archived and available for 30 days following the event.

Experic Appoints Philip Dunne as Director, EU Operations

Retrieved on: 
Wednesday, April 3, 2024
Other Manufacturing, Other Science, Practice Management, Medical Supplies, FDA, Research, Managed Care, Packaging, General Health, Logistics, Supply Chain Management, Manufacturing, Other Health, Pharmaceutical, Medical Devices, Clinical Trials, Transport, Biotechnology, Health, Science, Philip, GMP, Knowledge, CDMO, Clinical trial, GDP, Vaccine

Experic , a contract development and manufacturing organization (CDMO) and clinical trial supply services company serving the biopharmaceutical industry, today announced the appointment of Philip Dunne as Director of EU Operations, to head up initial operations of its recently announced 10,000 sq.

Key Points: 
  • Experic , a contract development and manufacturing organization (CDMO) and clinical trial supply services company serving the biopharmaceutical industry, today announced the appointment of Philip Dunne as Director of EU Operations, to head up initial operations of its recently announced 10,000 sq.
  • "We are delighted to have Philip on board to support our recent EU expansion," said Vice President of Operations, Brian Fagan.
  • "A seasoned industry professional, he brings a diversified skill set in pharmaceutical and medical device clinical trial supply services to the Experic team.
  • "I am very excited to be joining the Experic team to bring their first international facility online," shared Philip Dunne, Director of EU Operations.

VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

Retrieved on: 
Wednesday, April 3, 2024
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Toxicity, Combination therapy, SOC, Survival, Disease, Patient, GBM, Vaccine, Neoplasm, Decompression (diving), Safety, VBI, Pharmaceutical industry

The multi-center, randomized, controlled, open-label study has been designed to evaluate overall survival, tumor response rates, and safety and tolerability of VBI-1901 as a monotherapy in rGBM patients.

Key Points: 
  • The multi-center, randomized, controlled, open-label study has been designed to evaluate overall survival, tumor response rates, and safety and tolerability of VBI-1901 as a monotherapy in rGBM patients.
  • Dr. Anderson commented: “In recurrent GBM, tumors typically double or triple in size within six weeks, with no effective treatments available to improve survival.
  • Early indications from this ongoing study suggest tumor growth behavior in-line with expectations for both the standard-of-care arm and the VBI-1901 arm, based on positive data seen from the Phase 1/2a study.
  • As of March 22, 2024, 17 patients have been randomized 1:1 to either the active, VBI-1901 treatment arm, or to the control, standard-of-care treatment arm (SoC).

InfuSystem Receives Notice from NYSE American Regarding Late Filing of Annual Report on Form 10-K

Retrieved on: 
Wednesday, April 3, 2024
Medical Supplies, Medical Devices, Health, Practice Management, Other Health, General Health, Exchange, The, Classification, Security (finance), ASC, Annual report, File, Accounting, Delinquent, Medical device

In accordance with Section 1007 of the Company Guide, the Company will have six months from the date of the Filing Delinquency (the "Initial Cure Period"), to file the Delinquent Report with the SEC.

Key Points: 
  • In accordance with Section 1007 of the Company Guide, the Company will have six months from the date of the Filing Delinquency (the "Initial Cure Period"), to file the Delinquent Report with the SEC.
  • The Exchange will monitor the Company and the status of the Delinquent Report and any subsequent delayed filings, including through contact with the Company, until the Filing Delinquency is cured.
  • If the Company fails to file the Delinquent Report during the Initial Cure Period, the Exchange may, in its sole discretion, grant an up to six-month additional cure period (the "Additional Cure Period").
  • There can be no assurance that the Company will ultimately regain compliance with all applicable Exchange listing standards.

Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Tuesday, April 2, 2024
Research, Medical Devices, Genetics, Health Technology, Other Health, Biotechnology, Health, Science, Oncology, Other Science, Webcast, Castle, Conference

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 12:45 p.m. Eastern time.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 12:45 p.m. Eastern time.
  • A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx .
  • A replay of the webcast will be available following the conclusion of the live broadcast.

Summit Health Names Timothy Reish, M.D., Chair of Orthopedics and Sports Medicine, Pain Management and Podiatry

Retrieved on: 
Tuesday, April 2, 2024
Health, Surgery, Practice Management, Physical Therapy, Other Health, Managed Care, General Health, Knee, Shoulder, Orthopedic surgery, Patient, Franklin Avenue, Research, Pain management, Elbow, Summit Health, Summit, Sports medicine, Dentistry

Timothy Reish, M.D., has been named Chair of Orthopedics and Sports Medicine, Pain Management and Podiatry of Summit Health’s NY South region.

Key Points: 
  • Timothy Reish, M.D., has been named Chair of Orthopedics and Sports Medicine, Pain Management and Podiatry of Summit Health’s NY South region.
  • He has been a practicing Orthopedic Surgeon in New York City for more than 20 years.
  • “We are thrilled that Dr. Reish will be leading three of our key departments that are essential to the health and well-being of our patients throughout their lifetime,” said Christine Masterson, M.D., executive vice president at Summit Health.
  • “I look forward to helping our Orthopedics, and Sports Medicine, Pain Management and Podiatry departments stay at the forefront of healthcare by offering the latest advancements and cutting-edge techniques in the fields of Orthopedics and Sports Medicine, Pain Management and Podiatry,” said Dr. Reish.

Sail Biomedicines Appoints Clinical and Scientific Leader Dr. Wendy Chung to Its Board

Retrieved on: 
Tuesday, April 2, 2024
Research, Genetics, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Oncology, Principal, Harvard Medical School, Education, DSM-IV codes, Associate, Nanoparticle, Patient, Biomedicine, RNA, Flagship Pioneering, Columbia University, AI, Faculty, Personalized medicine, Panasonic Executive Partner, Infection, Hospital, Division, Therapy, Medical director, Genomics, Nursing

Sail Biomedicines, Inc. (“Sail”), a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that Wendy Chung, M.D., Ph.D., has joined Sail’s Board of Directors.

Key Points: 
  • Sail Biomedicines, Inc. (“Sail”), a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that Wendy Chung, M.D., Ph.D., has joined Sail’s Board of Directors.
  • Dr. Chung currently serves as Chief of the Department of Pediatrics of Boston Children’s Hospital, sits on the faculty at Harvard Medical School, and is President of the Children’s Hospital Pediatric Associates.
  • Dr. Chung brings to Sail’s board more than 20 years of experience as a clinical and molecular geneticist, as well as biotech operational experience.
  • “I’m thrilled to contribute to Sail’s mission to create breakthroughs for patients with new types of RNA therapeutics and to join Sail’s distinguished Board of Directors,” said Dr. Chung.

Merck Continues the Fight against Schistosomiasis in a Storytelling Lab

Retrieved on: 
Tuesday, April 2, 2024
Research, Infectious Diseases, Other Health, Other Education, Health, Pharmaceutical, General Health, Science, Education, Parasitism, Schistosomiasis, Disease, Tablet, SVP, Male, Health education, World Health Organization, Skin, Neglected tropical diseases, WHO, Multimedia, Ministry, Pharmaceutical industry

Merck, a leading science and technology company, announced the winners of its 2024 Bilharzia Storytelling Lab in Ethiopia.

Key Points: 
  • Merck, a leading science and technology company, announced the winners of its 2024 Bilharzia Storytelling Lab in Ethiopia.
  • This innovative initiative aims to develop creative solutions in order to raise awareness about schistosomiasis and, in doing so, bring about behavioral change.
  • View the full release here: https://www.businesswire.com/news/home/20240402803315/en/
    The winners of this year's Merck Bilharzia Storytelling Lab in Ethiopia (Photo: Business Wire)
    Schistosomiasis is one of the most prevalent parasitic diseases and affects more than 240 million people worldwide.
  • Read more about how Merck is committed to eliminating schistosomiasis: www.merckgroup.com/schistosomiasis
    View source version on businesswire.com: https://www.businesswire.com/news/home/20240402803315/en/

Oscar Health, Inc. 2024 First Quarter Conference Call

Retrieved on: 
Tuesday, April 2, 2024
Health, Practice Management, Other Health, Health Insurance, Managed Care, General Health, Biotechnology, OSCR

Oscar Health, Inc. (“Oscar”) (NYSE: OSCR), a leading healthcare technology company, will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024.

Key Points: 
  • Oscar Health, Inc. (“Oscar”) (NYSE: OSCR), a leading healthcare technology company, will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024.
  • Management will review these results in a conference call beginning at 8:00 AM (ET).
  • The call-in number and webcast link are as follows: